Scarica l'app Stockscreener
68.45
2.34%
-1.64
Pre-mercato:
68.30
-0.15
-0.22%
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Financials
Perché ARWR Giù?
Forum
Previsione
Frazionamento azionario
Arrowhead Pharmaceuticals Inc Borsa (ARWR) Ultime notizie
Arrowhead Pharmaceuticals reports inducement grants under Nasdaq Listing Rule 5635(c)(4) - marketscreener.com
Arrowhead Pharmaceuticals Reports Inducement Grants under NASDAQ Listing Rule 5635(c)(4) - Business Wire
36,469 Shares in Arrowhead Pharmaceuticals, Inc. $ARWR Acquired by Marex Group plc - MarketBeat
WINTON GROUP Ltd Invests $660,000 in Arrowhead Pharmaceuticals, Inc. $ARWR - MarketBeat
Arrowhead Pharma secures $200M milestone from Sarepta Therapeutics - MSN
RBC Capital Maintains Arrowhead Pharmaceuticals (ARWR) Outperform Recommendation - Nasdaq
Arrowhead Pharmaceuticals (NASDAQ:ARWR) Stock Price Expected to Rise, Royal Bank Of Canada Analyst Says - MarketBeat
Arrowhead Pharma (ARWR) Receives Raised Price Target from RBC Capital | ARWR Stock News - GuruFocus
Arrowhead Pharmaceuticals stock hits 52-week high at 71.62 USD - Investing.com
Arrowhead Pharma stock price target raised to $80 from $52 at RBC Capital - Investing.com Canada
Arrowhead Pharmaceuticals (ARWR) Valuation Check as ARO-MAPT Enters First Human Trial in Alzheimer’s Treatment - Yahoo Finance
History Review: Can Arrowhead Pharmaceuticals Inc stock surprise with earnings upsideJuly 2025 Closing Moves & Verified Momentum Stock Watchlist - moha.gov.vn
Michael Perry Sells 16,250 Shares of Arrowhead Pharmaceuticals (NASDAQ:ARWR) Stock - MarketBeat
B of A Securities Maintains Arrowhead Pharmaceuticals (ARWR) Buy Recommendation - Nasdaq
ARWR: B of A Securities Raises Price Target Amid Maintained Buy Rating | ARWR Stock News - GuruFocus
Bank of America Issues Positive Forecast for Arrowhead Pharmaceuticals (NASDAQ:ARWR) Stock Price - MarketBeat
Arrowhead Pharmaceuticals (NASDAQ:ARWR) Shares Gap DownTime to Sell? - MarketBeat
Arrowhead Pharmaceuticals (ARWR) Stock Soars on First FDA Approval, Novartis Deal and New Alzheimer’s Trial - ts2.tech
Arrowhead Pharmaceuticals Flourishes with Key Milestones and Growth Projections - StocksToTrade
Arrowhead Pharmaceuticals (ARWR) Soars to Fresh Highs on Alzheimer’s Trial and FDA Breakthrough Wins - ts2.tech
Arrowhead Pharmaceuticals stock soars after dosing first subjects in trial By Investing.com - Investing.com Australia
Arrowhead Pharmaceuticals stock soars after dosing first subjects in trial - Investing.com
Arrowhead Pharmaceuticals (NASDAQ:ARWR) Reaches New 1-Year HighTime to Buy? - MarketBeat
Arrowhead Hits the Mark - Los Angeles Business Journal
Arrowhead’s Plozasiran Garners FDA Breakthrough Recognition - timothysykes.com
Arrowhead (ARWR) Begins Trials for Alzheimer's Treatment - GuruFocus
Arrowhead Pharmaceuticals Initiates Phase 1/2a Study of ARO-MAPT for the Treatment of Alzheimer’s Disease and Other Tauopathies - Yahoo Finance
Marshall Wace LLP Grows Stock Position in Arrowhead Pharmaceuticals, Inc. $ARWR - MarketBeat
Norges Bank Invests $30.41 Million in Arrowhead Pharmaceuticals, Inc. $ARWR - MarketBeat
(ARWR) Movement Within Algorithmic Entry Frameworks - news.stocktradersdaily.com
Edgestream Partners L.P. Lowers Stock Holdings in Arrowhead Pharmaceuticals, Inc. $ARWR - MarketBeat
Arrowhead Pharmaceuticals (NASDAQ:ARWR) Stock Price Down 5%What's Next? - MarketBeat
Arrowhead Pharmaceuticals (ARWR) Price Target Increased by 17.24% to 59.24 - Nasdaq
Franklin Resources Inc. Purchases Shares of 81,226 Arrowhead Pharmaceuticals, Inc. $ARWR - MarketBeat
Analysts Conflicted on These Healthcare Names: Arrowhead Pharmaceuticals (ARWR) and Humana (HUM) - The Globe and Mail
Arrowhead Pharmaceuticals (ARWR) Valuation After FDA Breakthrough Therapy Designation for Plozasiran - Sahm
How Arrowhead Pharmaceuticals Inc. (HDP1) stock reacts to Fed tighteningEarnings Recap Summary & Risk Managed Investment Entry Signals - Newser
How analysts revise price targets for Arrowhead Pharmaceuticals Inc. (HDP1) stockPortfolio Value Report & Reliable Price Breakout Alerts - Newser
Fisher Asset Management LLC Has $7.14 Million Stock Position in Arrowhead Pharmaceuticals, Inc. $ARWR - MarketBeat
What dividend safety rating applies to Arrowhead Pharmaceuticals Inc. (HDP1) stockWeekly Loss Report & Long-Term Capital Growth Strategies - Newser
Is Arrowhead Pharmaceuticals Inc. (HDP1) stock cheap vs fundamentalsJuly 2025 Institutional & Intraday High Probability Alerts - Newser
Breakthrough Approved: FDA approves pioneering FCS drug by Pasadena company - Pasadena Weekly
HC Wainwright Issues Pessimistic Estimate for ARWR Earnings - MarketBeat
What is HC Wainwright's Estimate for ARWR Q2 Earnings? - MarketBeat
Why Arrowhead Pharmaceuticals Inc. (HDP1) stock is favored by hedge fundsJuly 2025 Summary & Low Drawdown Trading Strategies - Newser
Arrowhead Pharmaceuticals Poised for Growth Following Breakthrough FDA Approvals - StocksToTrade
ARWR’s Meteoric Rise: Can It Sustain? - timothysykes.com
Arrowhead Pharmaceuticals (NASDAQ:ARWR) Hits New 52-Week High After Analyst Upgrade - MarketBeat
ARWR: Plozasiran launch, pipeline advances, and strong partnerships drive growth and innovation - TradingView
Arrowhead (ARWR) Stock Sees 9.7% Rise Following Market Activity - GuruFocus
Arrowhead Pharmaceuticals Soars with FDA Breakthrough Therapy Designation - timothysykes.com
Arrowhead Pharmaceuticals (NASDAQ:ARWR) Stock Price Expected to Rise, HC Wainwright Analyst Says - MarketBeat
Arrowhead Pharma stock price target raised to $85 by H.C. Wainwright - Investing.com UK
Have Arrowhead Pharmaceuticals Insiders Been Selling Stock? - simplywall.st
Creative Planning Buys 19,194 Shares of Arrowhead Pharmaceuticals, Inc. $ARWR - MarketBeat
How Arrowhead Pharmaceuticals Inc. (HDP1) stock behaves under inflation pressure2025 Valuation Update & Accurate Entry and Exit Point Alerts - Newser
Will Arrowhead Pharmaceuticals Inc. (HDP1) stock outperform global peers2025 Macro Impact & AI Enhanced Trading Alerts - Newser
Arrowhead Pharmaceuticals (NASDAQ:ARWR) Director Mauro Ferrari Sells 8,750 Shares - MarketBeat
Arrowhead Pharmaceuticals (NASDAQ:ARWR) Stock Price Up 4.7% on Analyst Upgrade - MarketBeat
Arrowhead Pharmaceuticals stock hits 52-week high at 59.19 USD By Investing.com - Investing.com India
Arrowhead Pharmaceuticals stock hits 52-week high at 59.19 USD - Investing.com
Arrowhead Pharmaceuticals, Inc.'s (NASDAQ:ARWR) Share Price Boosted 33% But Its Business Prospects Need A Lift Too - 富途牛牛
Bank of America Forecasts Strong Price Appreciation for Arrowhead Pharmaceuticals (NASDAQ:ARWR) Stock - MarketBeat
Arrowhead Pharmaceuticals (ARWR) Gains FDA Breakthrough Therapy Designation - GuruFocus
Arrowhead Pharmaceuticals gets FDA Breakthrough Therapy status for plozasiran - Seeking Alpha
0.36%
1.05%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):